drugset / Trial / NCT00380601
PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
An open-label, PhaseⅢ study to evaluate the efficacy and safety of MRA in patients with RA
Timeline
- Start
- 2006-05
- Primary completion
- 2008-08
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | — |